David Gastfriend, MD, DFASAM, explained to NCAD attendees how technology platforms can help providers overcome obstacles to adopting contingency management programs that have been proven to effectively augment traditional treatment modalities.
At NCAD, Kevin McCauley, MD, explained to NCAD attendees how, much like aviation safety checklists help Navy pilots avoid mishaps, recovery plans protect individuals in addiction treatment stay sober when they otherwise might struggle to make proper decisions.
Although many treatment centers are under-resourced, Jamie Marich, PhD, LPCC-S, LICDC-CS, REAT, RYT-200, said in her NCAD session that trauma must be addressed as a root cause of many addiction disorders.
Fueled by personal experiences, Peggy Terhune, PhD, leads North Carolina-based Monarch with a vision of continuous improvement and innovation, and a trauma-informed approach to treatment for patients and their families.
Concerns over patient isolation, staff safety and licensing reciprocity between states as a means to address a shortage of care providers during a crisis were among the COVID-19-related topics discussed by a panel of industry leaders during a Friday morning session at the virtual National Conference on Addiction Disorders.
In a wide-ranging Q&A session at NCAD on Thursday, Cameron Douglas discussed his time in incarceration for drug-related offenses, his best-selling book about his journey in recovery titled “Long Way Home,” and how he is now maintaining his sobriety.
Robert DuPont, MD, president of the Institute for Behavior and Health, said in his session at NCAD that results from state physician health programs signal a paradigm shift for achieving better addiction treatment outcomes in the general population.
To be effective and ethical in taking care of patients, practitioners also must take care of themselves. Making organizational culture changes that prioritize self-care for staff starts with changing the conversation, says Tara Matthews, PhD, LPC, MAC.
Changing business practices among cartels and the impact of COVID-19 on the supply chain of illicit substances are among the topics practitioners treating substance use disorders should be aware of, says Derek Osborn, CPS, CPM, of DrugUniversity.org.
Stay in the know. Psychiatry and Behavioral Health Learning Network Newsletter